Dermatomycoses - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dermatomycoses - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dermatomycoses - Pipeline Review, H1 2016', provides an overview of the Dermatomycoses pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Dermatomycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dermatomycoses
- The report reviews pipeline therapeutics for Dermatomycoses by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Dermatomycoses therapeutics and enlists all their major and minor projects
- The report assesses Dermatomycoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Dermatomycoses


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Dermatomycoses
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dermatomycoses pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dermatomycoses Overview 6
Therapeutics Development 7
Pipeline Products for Dermatomycoses - Overview 7
Pipeline Products for Dermatomycoses - Comparative Analysis 8
Dermatomycoses - Therapeutics under Development by Companies 9
Dermatomycoses - Therapeutics under Investigation by Universities/Institutes 10
Dermatomycoses - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Dermatomycoses - Products under Development by Companies 15
Dermatomycoses - Products under Investigation by Universities/Institutes 16
Dermatomycoses - Companies Involved in Therapeutics Development 17
Anacor Pharmaceuticals, Inc. 17
Blueberry Therapeutics Ltd 18
Daewoong Pharmaceutical Co., Ltd. 19
Helix BioMedix, Inc. 20
TGV-Laboratories 21
Viamet Pharmaceuticals, Inc. 22
Dermatomycoses - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
AN-2718 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
BB-2603 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dapaconazole - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DWP-06081 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HB-1275 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Myc-102 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule for Fungal Infections - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
VT-1161 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Dermatomycoses - Recent Pipeline Updates 41
Dermatomycoses - Dormant Projects 45
Dermatomycoses - Product Development Milestones 46
Featured News & Press Releases 46
Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis 46
Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Number of Products under Development for Dermatomycoses, H1 2016 7
Number of Products under Development for Dermatomycoses - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Comparative Analysis by Unknown Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Dermatomycoses - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 17
Dermatomycoses - Pipeline by Blueberry Therapeutics Ltd, H1 2016 18
Dermatomycoses - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 19
Dermatomycoses - Pipeline by Helix BioMedix, Inc., H1 2016 20
Dermatomycoses - Pipeline by TGV-Laboratories, H1 2016 21
Dermatomycoses - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Dermatomycoses Therapeutics - Recent Pipeline Updates, H1 2016 41
Dermatomycoses - Dormant Projects, H1 2016 45